Switzerland Archives

In Depth 25 Jan 2018

What Happened to the Plans for a Smart Contact Lens for Diabetics?

Originally projected to be on the market by 2020, excitement about the contact lens to measure glucose levels from Novartis and Google has waned. Why? In 2016, smart wearables growth was steady but a recent study predicts that the market will pick up this year introducing innovative products to the consumer market: according to CCS Insight, the market for […]

January 25, 2018 - 5 minutesmins - By External Contributor

News and Trends 22 Jan 2018

Novartis Takes Genmab’s Leukemia Drug Off the Market

Genmab’s leukemia drug will be available around the world through compassionate use programs, while it will continue to be marketed as normal in the US. Blockbuster drug owner Genmab developed Arzerra for the treatment of chronic lymphocytic leukemia (CLL) but the drug will be taken off the market outside the US due to its low uptake. Novartis markets the drug and […]

January 22, 2018 - 3 minutesmins - By Alex Dale

alzheimers disease acimmune andrea pfeifer 1

Interview 8 Jan 2018

Meet the Swiss CEO Pulling Out All the Stops Against Alzheimer’s Disease

Efforts to treat Alzheimer’s Disease have been hit with failure after failure in the last year or so. Andrea Pfeifer, co-founder and CEO of AC Immune, told me about how her company hopes to pull off a win. Andrea Pfeifer started out as toxicologist in oncology before she moved into entrepreneurship. She left Germany after […]

January 8, 2018 - 8 minutesmins - By Evelyn Warner

News and Trends 14 Dec 2017

A Breath of Fresh Air for Biotechs Working on Cystic Fibrosis Therapies?

Researchers from the University of Zurich have determined the structure of a chloride channel, which could be a target for new drugs to treat cystic fibrosis. Researchers at the University of Zurich have found a new target for future cystic fibrosis treatments. The study, published in Nature, has uncovered the structure of a protein that could help to […]

December 14, 2017 - 3 minutesmins - By Alex Dale

CRISPR Therapeutics clinical trials CRISPR Cas9

News and Trends 13 Dec 2017

CRISPR Therapeutics Plans First CRISPR/Cas9 Clinical Trial in Europe for 2018

CRISPR Therapeutics and Vertex Pharmaceuticals are taking action to start a first clinical trial with CRISPR/Cas9 in Europe in 2018. The blood disorder β-thalassemia could soon be the first human disease to be treated using CRISPR/Cas9 technology in Europe. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have announced the first candidate from their collaboration that will go […]

December 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Dec 2017

Taking Aim at Lung Cancer: New Triple Combination Therapy Boosts Survival

A new first-line combination therapy for advanced non-squamous non-small-cell lung cancer improved progression-free survival during a Phase III trial. Scientists based at the Lung Clinic Grosshansdorf, Hamburg, and Centre Hospitalier Universitaire Vaudois, Lausanne, have presented the results of a Phase III study at the ESMO Immuno Oncology Congress 2017. The study was the first to investigate a combination […]

December 7, 2017 - 3 minutesmins - By Alex Dale

hypertension treatment idorsia janssen2 1

News and Trends 4 Dec 2017

Swiss Biotech Brings in Reinforcements to See Hypertension Drug Through Phase III

Idorsia will collaborate with Janssen on the development of its hypertension drug, aprocitentan, which could help to prevent future heart attacks and strokes. Idorsia was born out of Actelion’s massive $30B (€27.9B) acquisition by Johnson & Johnson, retaining all of the former biotech’s early-stage assets. The company develops small molecules for a broad range of […]

December 4, 2017 - 3 minutesmins - By Alex Dale

News and Trends 29 Nov 2017

What Exactly Happens in the Cells of People with Down’s Syndrome?

Researchers in Switzerland have taken a closer look at the cells of Down’s syndrome patients, with widespread changes in protein expression observed. Down’s syndrome, or trisomy 21, is the most common genetic disease, characterized by facial dysmorphism, learning disabilities, poor muscle tone and heart problems. Research carried out at the University of Geneva and ETH […]

November 29, 2017 - 3 minutesmins - By Alex Dale

News and Trends 28 Nov 2017

A Treatment for Sudden Deafness Fails in Phase III

Auris Medical’s treatment for sudden deafness has failed to meet its efficacy endpoint, leading the company to terminate a second trial early. Based in Zug, Switzerland, Auris Medical is developing what could be the first treatments for inner ear disorders such as hearing loss, tinnitus, and vertigo. But today, the company suffered a setback. Its lead […]

November 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Nov 2017

The Link Between Type 2 Diabetes and Obesity may have Finally been Uncovered

Researchers at the Université de Genève have unravelled the cellular and molecular mechanisms linking obesity and insulin resistance. We have long known about a link between obesity and type 2 diabetes, but discovering the underlying mechanisms has proved difficult. A group of researchers at the Université de Genève, Switzerland, may have found a protein that links changes […]

November 28, 2017 - 3 minutesmins - By Alex Dale

Interview 27 Nov 2017

A First Treatment for Hearing Loss, Tinnitus and Vertigo? Meet the Man Behind It

Thomas Meyer, CEO of Auris Medical, discusses how biotech can finally bring solutions to those who live with hearing loss, tinnitus and vertigo. Thomas Meyer is at the forefront of a wave of drugs that could, for the first time, show efficacy in treating common hearing disorders. In 2003, he founded Auris Medical to address […]

November 27, 2017 - 10 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2017

Swiss Biotech Rakes in Biggest Fundraising of 2017 to Regenerate Heart Valves

Xeltis has raised a €45M Series C to boost the development of its pioneering medical device, RestoreX, which helps to replace damaged heart valves. Xeltis, based in Zurich, Switzerland, is a clinical-stage medical device company developing heart valves and blood vessels to allow the body to naturally restore heart valve function. The biotech has achieved a €45M […]

November 15, 2017 - 2 minutesmins - By Alex Dale

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Switzerland

What Happened to the Plans for a Smart Contact Lens for Diabetics?

Novartis Takes Genmab’s Leukemia Drug Off the Market

Meet the Swiss CEO Pulling Out All the Stops Against Alzheimer’s Disease

A Breath of Fresh Air for Biotechs Working on Cystic Fibrosis Therapies?

CRISPR Therapeutics Plans First CRISPR/Cas9 Clinical Trial in Europe for 2018

Taking Aim at Lung Cancer: New Triple Combination Therapy Boosts Survival

Swiss Biotech Brings in Reinforcements to See Hypertension Drug Through Phase III

What Exactly Happens in the Cells of People with Down’s Syndrome?

A Treatment for Sudden Deafness Fails in Phase III

The Link Between Type 2 Diabetes and Obesity may have Finally been Uncovered

A First Treatment for Hearing Loss, Tinnitus and Vertigo? Meet the Man Behind It

Swiss Biotech Rakes in Biggest Fundraising of 2017 to Regenerate Heart Valves

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!